Neuren Pharmaceuticals Ltd (ASX: NEU) shares are back in focus on Wednesday.
This comes after the biotech company announced a new commercial milestone for its lead Rett syndrome therapy.
In early afternoon trade, the Neuren share price is up 6.75% to $13.13. By comparison, the S&P/ASX 200 Index (ASX: XJO) is rocketing 2.6% higher to 8,957 points.
Today's rise stands out because the stock is still down roughly 30% since the start of 2026.
Let's take a closer look at the release.
Image source: Getty Images
DAYBUE STIX rollout reaches the next stage
The catalyst for Wednesday's gain is a fresh commercial milestone from ACADIA Pharmaceuticals Inc (NASDAQ: ACAD), Neuren's US partner for DAYBUE.
According to the release, DAYBUE STIX is now broadly available across the United States for patients with Rett syndrome.
The new powder formulation was approved by the US Food and Drug Administration (FDA) in December and first launched on a limited basis during the March quarter.
This update confirms the rollout has now moved into wider commercial distribution, giving more patients and caregivers access to the therapy.
The new formulation gives families more flexibility because it can be mixed with water-based liquids, making it easier to adjust taste and dose volume.
Management also pointed to encouraging early caregiver feedback from the limited launch, with more than 80% of surveyed users reporting satisfaction.
Broader rollout supports the royalty outlook
Neuren receives royalties on all global net sales of trofinetide under its licensing agreement with Acadia. As a result, commercial rollout milestones usually have a direct impact on the share price.
At its FY25 result, the company reported royalty income of $65 million and guided to a further lift in 2026 as DAYBUE sales continue to expand.
Acadia's 2026 guidance previously pointed to DAYBUE net sales of US$460 million to US$490 million, which implies another year of solid revenue growth for Neuren.
With a market capitalisation of roughly $1.56 billion, the stock remains well below the peaks seen in 2025.
Foolish Takeaway
Neuren's latest gain follows broader US access to DAYBUE STIX, a rollout step that could support patient growth and future royalties.
Based on the company's strong February result and Acadia's 2026 sales guidance, I still see Neuren as one of the more compelling ASX biotech investments.
The combination of DAYBUE revenue growth and progress across the NNZ-2591 pipeline continues to reinforce the long-term opportunity.
After a difficult start to 2026, today's move may be an early sign that confidence is rebuilding around the company's revenue outlook.
